

**AMENDMENT**

**U.S. Appln. No. 09/599,002**

**IN THE SPECIFICATION:**

The specification is amended as follows:

Page 9, lines 14-28, are amended as follows:

FcγRIIA

EC2-131R : 5'CCAGAATGGAAAATCCCAGAAATTCTCTCG3' (SEQ ID NO:1)  
EC2-131H : 5'CCAGAATGGAAAATCCCAGAAATTCTCTCA3' (SEQ ID NO:2)  
TM1 : 5'CCATTGGTGAAGAGCTGCCCATGCTGGGCA3' (SEQ ID NO:3)  
Control 1 : 5'GATTCAGTGACCCAGATGGAAGGG3' (SEQ ID NO:4)  
Control 2 : 5'AGCACAGAAGTACACCGCTGAGTC3' (SEQ ID NO:5)

FcγRIIA

NA1 : 5'CAGTGGTTTCACAATGTGAA3' (SEQ ID NO:6)  
NA2 : 5'CAATGGTACAGCGTGCTT3' (SEQ ID NO:7)  
Reverse primer : 5'ATGGACTTCTAGCTGCAC3' (SEQ ID NO:8)  
Control 1 : 5'CAGTGCTTCCCAACCATTCCCTTA3' (SEQ ID NO:9)  
Control 2 : 5'ATCCACTCACGGATTTCTGTTGTGTTTC3' (SEQ ID NO:10)

Page 11, between lines 1-5 are amended as follows:  
drawings in which:

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a plot of the probability of multiple sclerosis patients being able to walk without support (crutches or cane) correlated to duration of disease and FcγRIIIB genotype; and